28 results on '"Hiroyuki Sonoda"'
Search Results
2. Long-term neurodevelopmental changes in subjects with MPS II following long-term treatment with pabinafusp alfa: An integrated analysis from pre- and post-approval clinical trials in Brazil and Japan
3. Life-span extension in Krabbe disease mice by treatment with a transferrin receptor-targeted galactocerebrosidase
4. A fusion protein of anti-human transferrin receptor antibody and alfa-L-fucosidase 1 is a prospective candidate for the treatment of the symptoms in CNS and visceral tissues of fucosidosis
5. Intravenous treatment with pabinafusp alfa dose-dependently prevents neurological impairment and bone deformities in a mouse model of mucopolysaccharidosis type II
6. Real-world data of enzyme replacement therapy with pabinafusp alfa for neuronopathic MPS-II: Updated clinical data from Japan
7. Treatment of CLN1 disease with a blood-brain barrier penetrating lysosomal enzyme AGT-194
8. Drug delivery for neuronopathic lysosomal storage diseases: evolving roles of the blood brain barrier and cerebrospinal fluid
9. Suppression of anti-alpha-GalA antibody production by blockade of T-cell costimulation in mice
10. Efficacy of an anti-human transferrin receptor antibody-fused N-sulfoglucosamine sulfohydrolase in mucopolysaccharidosis type IIIA mice
11. Non-clinical evaluation of a blood-brain barrier-penetrable N-sulfoglucosamine sulfohydrolase in a mouse model of mucopolysaccharidosis type IIIA
12. Exploration of the efficacy of pabinafusp-alfa (JR-141) on neurocognitive development in Hunter syndrome (MPS II): 52-week data from clinical trials in Japan and Brazil
13. Non-clinical evaluation of a blood-brain barrier-penetrable a--acetylglucosaminidase in a mouse model of mucopolysaccharidosis type IIIB
14. Therapy for mucopolysaccharidosis type II with an intravenous blood-brain barrier-crossing enzyme (JR-141): Phase III global clinical trial design
15. Usefulness of hexose tetrasaccharide as a biomarker for monitoring glycogen accumulation in peripheral tissues and brain in Pompe disease
16. Drug delivery across the blood-brain barrier and resultant reduction of heparan sulfate in the cerebrospinal fluid in the patients with Hunter syndrome (MPS II): An integrated analysis of 25-week Japanese and Brazilian data on pabinafusp alfa (JR-141)
17. Reduction of heparan sulfate in the brain by pabinafusp alfa results in prevention of neurodegeneration and neurocognitive impairment in a mouse model of mucopolysaccharidosis type II
18. The retinol-retinoic acid metabolic pathway is impaired in the lumbar spine of a rat model of congenital kyphoscoliosis
19. Effects of cytoplasmic and periplasmic chaperones on secretory production of single-chain Fv antibody in Escherichia coli
20. Cytoplasmic production of soluble and functional single-chain Fv-Fc fusion protein in Escherichia coli
21. Efficient production of active Vibrio proteolyticus aminopeptidase in Escherichia coli by co-expression with engineered vibriolysin
22. Extracellular production of active vibriolysin engineered by random mutagenesis in Escherichia coli
23. Improved Solubilization of Recombinant Human Growth Hormone Inclusion Body Produced inEscherichia coli
24. Correction of central nervous system deficits in the mouse model of Hunter syndrome by recombinant iduronate 2-sulfatase crossing the blood-brain barrier
25. Blood-brain barrier-penetrating iduronate-2-sulfatase reduces brain glycosaminoglycans in mouse model of mucopolysaccharidosis type II
26. Production of Antibody Fragments in Escherichia coli
27. Functional expression of single-chain Fv antibody in the cytoplasm of Escherichia coli by thioredoxin fusion and co-expression of molecular chaperones
28. Influence of immune response on reduction of glycosaminoglycan (GAG) substrates in immunized MPS II mice
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.